The Peter Attia Drive

#373 – Thyroid function and hypothyroidism: why current diagnosis and treatment fall short for many, and how new approaches are transforming care | Antonio Bianco, M.D., Ph.D.

November 17, 2025

Key Takeaways Copied to clipboard!

  • Thyroid hormone action is primarily mediated by the active form, T3, which is generated from the secreted prohormone T4 via deiodinase enzymes, allowing for localized, tissue-specific regulation of hormone activity. 
  • The T3 to reverse T3 ratio serves as a crucial surrogate marker for estimating deiodinase activity, as fasting or low energy states shift T4 conversion away from active T3 toward inactive reverse T3 to conserve energy. 
  • Standard clinical practice of relying solely on TSH and free T4 is insufficient for diagnosing or managing hypothyroidism because the biologically active hormone T3, and the quality of its measurement (immunoassays being poor for T3/rT3), are critical components of thyroid physiology that are often overlooked. 
  • The standard diagnostic reliance on TSH and Free T4 alone can miss symptomatic hypothyroidism, as illustrated by patients losing jobs despite 'normal' labs, prompting Dr. Bianco to refocus his research. 
  • The standard of care for Hashimoto's disease focuses on thyroid hormone replacement (Levothyroxine/T4 monotherapy), as treating the underlying autoimmunity is not standard practice, though antioxidants like selenium and Vitamin D may slow thyroid destruction. 
  • Retrospective data suggests that Levothyroxine monotherapy is associated with a 2.5-fold increased mortality compared to euthyroid controls, and combination T4/T3 therapy showed a 30% relative risk reduction in mortality compared to Levothyroxine alone, indicating incomplete restoration of euthyroidism with T4 monotherapy. 
  • The upper limit of normal for TSH should increase by one point every 10 years after age 50, meaning a TSH of 6 might be considered totally normal for a 70-year-old. 
  • Future improvements in hypothyroidism treatment require better methods for measuring T3, specifically mandatory use of MassPAC for T3 assays, and the pharmaceutical development of a slow-release T3 medication. 
  • The biggest blind spot in current thyroid care is the lack of effective treatment options, necessitating a move away from solely normalizing TSH to actively addressing patient suffering. 

Segments

Introduction and Guest Background
Copied to clipboard!
(00:00:10)
  • Key Takeaway: Dr. Antonio Bianco is a leading expert in thyroid physiology, focusing his research on deiodinase enzymes and thyroid hormone regulation at the tissue level.
  • Summary: Peter Attia introduces the episode focusing on thyroid function, diagnosis, and treatment shortcomings with expert Dr. Antonio Bianco. Dr. Bianco’s research centers on understanding thyroid hormone action in different tissues and the role of deiodinases in modulating hormone activity. The episode aims to clarify the complexities surrounding T3/T4 therapy and lab interpretation.
Thyroid Hormone Production Basics
Copied to clipboard!
(00:06:26)
  • Key Takeaway: The thyroid gland traps iodine to produce T4, an inactive prohormone stored in large amounts, which is then converted to the active hormone T3 by removing one iodine atom.
  • Summary: The thyroid requires dietary iodine to synthesize thyroid hormone, storing it primarily as T4. T4 becomes the active hormone T3 when a single iodine atom is removed, a process necessary because tissue receptors bind T3 with high affinity but T4 poorly. This mechanism evolved to conserve iodine, as T4 has a long half-life (about eight days) while active T3 is rapidly cleared (about 12 hours).
Deiodinases and Hormone Inactivation
Copied to clipboard!
(00:11:08)
  • Key Takeaway: Deiodinases control thyroid activity by either activating T4 to T3 (D2) or inactivating it by creating the biologically inert reverse T3 (D3).
  • Summary: Removing the iodine from the inner ring of T4 creates reverse T3 (rT3), which is biologically inactive, unlike T3 formed by removing the outer ring iodine. D2 is the primary enzyme for T3 production (80% outside the thyroid), while D3 is the main enzyme for inactivating T3 into T2 and converting T4 into rT3. The T3 to reverse T3 ratio is a useful surrogate for estimating deiodinase activity.
Fasting Effects on Thyroid Hormones
Copied to clipboard!
(00:13:04)
  • Key Takeaway: Fasting triggers the hypothalamus to slow energy expenditure by preferentially shunting T4 toward reverse T3 production and decreasing D1 activity, leading to lower T3 and elevated rT3.
  • Summary: During fasting, low insulin and leptin signal the hypothalamus to conserve energy by reducing thyroid hormone action. This results in lower T3 levels and a significant increase in reverse T3, as T4 conversion shifts toward the inactive rT3 pathway. Furthermore, D1 activity in the liver, sensitive to carbohydrate intake, decreases, slowing the clearance of reverse T3 and causing it to build up.
HPT Axis Regulation and Testing
Copied to clipboard!
(00:23:42)
  • Key Takeaway: The hypothalamus releases TRH to stimulate pituitary TSH release, which then stimulates the thyroid; TSH itself has no direct symptomatic effect on tissues, only acting via the thyroid gland.
  • Summary: The HPT axis involves the hypothalamus (TRH) controlling the pituitary (TSH), which controls the thyroid (T4). Central hypothyroidism occurs if the hypothalamus or pituitary fails to produce TSH, regardless of thyroid gland health. TSH levels only reflect the feedback loop; symptoms of hypo- or hyperthyroidism are caused by the resulting T3/T4 levels, not the TSH level itself.
Free vs. Total Hormone Measurement
Copied to clipboard!
(00:36:06)
  • Key Takeaway: Only the unbound, free fraction of thyroid hormones (free T3 and free T4) is biologically active, necessitating measurement of the free form, although T3 assays are generally less reliable than T4 assays.
  • Summary: Over 99.5% of circulating T3 and T4 are bound to transport proteins like TBG, rendering them inactive until they detach. Conditions affecting these proteins (like estrogen in pregnancy) alter total hormone levels without affecting the biologically relevant free fraction. Current standard immunoassays for T3 and reverse T3 are often poor, and mass spectrometry (LCMS) is needed for accurate T3 measurement, similar to best practices for sex hormones.
Hyperthyroidism Causes and Treatment
Copied to clipboard!
(00:46:05)
  • Key Takeaway: Hyperthyroidism is far less common than hypothyroidism, primarily caused by Graves’ disease (autoimmune stimulation) or autonomous hot nodules, with treatment options including medication, surgery, or radioactive iodine.
  • Summary: Graves’ disease involves stimulating antibodies mimicking TSH, leading to high T3/T4 and suppressed TSH, often treated medically with drugs that inhibit hormone production, or definitively with surgery or radioactive iodine. Hot nodules cause hyperthyroidism autonomously and will not go into remission with medication, making surgery or radioactive iodine the likely definitive treatments. There is growing concern regarding long-term cancer risk associated with radioactive iodine treatment.
Hypothyroidism Etiology and Autoimmunity
Copied to clipboard!
(00:56:40)
  • Key Takeaway: The most common cause of hypothyroidism is Hashimoto’s disease, an autoimmune condition where antibodies destroy the thyroid gland, but the presence of TPO antibodies alone is associated with other autoimmune risks, such as pregnancy complications.
  • Summary: Today, hypothyroidism is usually diagnosed via routine screening showing elevated TSH rather than presenting with overt symptoms. Hashimoto’s disease involves immune destruction of the thyroid, leading to reduced hormone production. The presence of TPO antibodies, even without overt hypothyroidism, is linked to increased risks of miscarriage and preterm birth, suggesting the autoimmune process is not strictly confined to the thyroid gland.
Origin of Hypothyroidism Interest
Copied to clipboard!
(01:05:11)
  • Key Takeaway: Symptomatic patients with normal TSH and T4 levels motivated a shift in research focus toward underlying hypothyroidism issues.
  • Summary: Dr. Bianco became interested in hypothyroidism after two separate patients, both math teachers, lost their jobs due to brain fog and lack of energy, despite having normal TSH and T4 labs. Both patients had their thyroids removed, suggesting a fundamental change occurred post-thyroidectomy that standard labs failed to capture. This experience prompted him to refocus his research into the complexities of thyroid function.
Autoimmune Thyroiditis Causes
Copied to clipboard!
(01:07:25)
  • Key Takeaway: Hashimoto’s is the prototypical autoimmune hypothyroidism, but other non-named autoimmune or inflammatory conditions, like subacute thyroiditis, can also destroy thyroid function.
  • Summary: Hashimoto’s disease is defined by the presence of the TPO antibody, but other forms of autoimmune thyroid disease exist without a specific name. Subacute thyroiditis involves severe, painful inflammation that rapidly destroys the thyroid gland, indicating inflammation beyond just Hashimoto’s. TPO and antithyroglobulin antibodies are specific markers because they target proteins exclusively produced in the thyroid.
Treating Autoimmunity and Diagnosis
Copied to clipboard!
(01:09:08)
  • Key Takeaway: Standard care for Hashimoto’s focuses only on replacement therapy, not treating the autoimmunity, although antioxidants like selenium may slow the destructive process by reducing free radicals generated during hormone synthesis.
  • Summary: The diagnosis of primary hypothyroidism mandates a high TSH (typically >10) concurrent with a reduced Free T4 level; a positive TPO antibody alone with a TSH of 4 is considered the ‘honeymoon phase.’ The peroxidation reaction involved in thyroid hormone synthesis creates damaging free radicals, which antioxidants may mitigate, potentially prolonging the thyroid’s function. If Free T4 is normal, even with an elevated TSH, the thyroid is still producing hormone, suggesting treatment is not yet mandatory based on labs alone.
Thyroid Replacement Therapy Options
Copied to clipboard!
(01:15:19)
  • Key Takeaway: Levothyroxine (T4) monotherapy is the FDA-approved standard of care, while T3 monotherapy is not recommended due to its short half-life causing symptomatic spikes.
  • Summary: T4 is the standard replacement because it is the prohormone, relying on peripheral deiodinases for activation, whereas T3 monotherapy is rarely used because its short half-life leads to undesirable peaks and troughs. Desiccated thyroid extract (DTE), derived from pig thyroid, contains both T4 and T3 in a natural ratio (around 4:1) and has been grandfathered in without modern FDA indication, despite having standardized potency since 1985. Studies suggest DTE and synthetic T4/T3 combination therapy are preferred by patients over T4 monotherapy and show similar safety profiles to Levothyroxine.
Mortality and Levothyroxine Efficacy
Copied to clipboard!
(01:27:41)
  • Key Takeaway: Retrospective analysis shows Levothyroxine-treated hypothyroid patients have 2.5 times greater mortality, often due to uncorrected cardiometabolic issues like elevated cholesterol, which persists even when TSH is normalized.
  • Summary: Levothyroxine was approved without clinical trials demonstrating efficacy beyond normalizing TSH, and retrospective data links its use to increased mortality, primarily from cardiometabolic diseases. The persistence of elevated LDL cholesterol in treated patients suggests that T4 monotherapy fails to restore euthyroidism in critical tissues like the liver, necessitating statin co-prescription. Combination therapy (T4/T3) demonstrated a 30% reduction in mortality relative to Levothyroxine alone, suggesting the addition of T3 provides systemic benefits.
Diagnosis vs. Treatment Approach
Copied to clipboard!
(01:36:07)
  • Key Takeaway: For diagnosing hypothyroidism, T3 levels are irrelevant because the body defends T3 homeostasis until overt failure, but for treatment assessment, symptoms are insufficient, requiring reliance on biochemical markers like TSH and Free T4.
  • Summary: T3 has no role in diagnosing hypothyroidism because the system prioritizes maintaining normal T3 levels by elevating TSH and lowering T4 when challenged. Symptoms like low temperature, fatigue, and weight gain are not pathognomonic for hypothyroidism and can be caused by confounding factors like menopause, making biochemical confirmation essential for diagnosis. Secondary hypothyroidism is a rare entity defined by low Free T4 with a non-elevated TSH, requiring pituitary/hypothalamus imaging.
Compounding and TSH Interpretation
Copied to clipboard!
(01:43:02)
  • Key Takeaway: Compounded controlled-release T3 lacks scientific basis for slow release, and extremely high TSH levels (e.g., 74.7) in symptomatic patients on therapy may indicate assay interference from heterophile antibodies rather than true pituitary overdrive.
  • Summary: There is no published pharmacokinetic evidence supporting the slow-release profile of compounded T3 products, and measuring low microgram doses is technically challenging due to necessary dilution methods. In cases of extremely high TSH with low-normal Free T4 despite treatment, assay interference from antibodies against rodent proteins (used in assay generation) is a strong possibility. For patients with non-linear pituitary responses or extremely high TSH values, Free T4 becomes the more reliable marker for titration than TSH.
Iodine Risks and Sex Differences
Copied to clipboard!
(02:05:45)
  • Key Takeaway: Excessive iodine supplementation significantly increases the risk of developing autoimmune thyroid disease (hypothyroidism), and women are 10 times more likely to develop hypothyroidism than men, a disparity without a clear explanation.
  • Summary: Daily iodine intake should be around 150 mcg for adults, and excessive intake (like the 500-600 mcg common in Japan) is known to trigger autoimmune thyroid disease. The 10-to-1 incidence ratio of hypothyroidism in women versus men is enormous, possibly related to women leaking slightly more thyroid antigens, though this is not fully explained by pregnancy alone. For subclinical hypothyroidism (elevated TSH, normal Free T4) in younger patients, treatment is often favored due to the risk of progression and metabolic benefits, whereas in older patients (over 50), TSH naturally increases with age, warranting less intervention.
Age-Adjusted TSH Limits
Copied to clipboard!
(02:12:39)
  • Key Takeaway: TSH upper limit of normal increases by one point every decade after age 50.
  • Summary: For diagnostic purposes, the acceptable upper limit of normal for TSH increases with age; for an 80-year-old, a TSH of 8 is considered acceptable, and for a 100-year-old, a TSH of 10 is acceptable. Physicians should not consider treating patients based on TSH levels that fall within these age-adjusted normal ranges. This adjustment means a 70-year-old with a TSH of 6 is considered totally normal and should not be prescribed levothyroxine based on that value alone.
Future Thyroid Treatment Needs
Copied to clipboard!
(02:13:24)
  • Key Takeaway: Improving hypothyroidism treatment requires better T3 measurement and developing slow-release T3 pharmaceuticals.
  • Summary: The field needs to improve treatment for the 20 million individuals suffering from hypothyroidism by moving beyond normalizing TSH. A mandatory step is developing a reliable, robust method for measuring T3 in circulation, preferably using MassPAC. The pharmaceutical industry must develop a slow-release T3 formulation to mimic natural thyroid function and give physicians confidence in combination therapy.
Slow-Release T3 Development
Copied to clipboard!
(02:15:05)
  • Key Takeaway: Two distinct slow-release T3 strategies are being developed: polymer breakdown and sulfated T3 conversion.
  • Summary: One approach involves a polymer that slowly breaks down T3 in the intestine, which is currently working with the FDA via the 505B2 regulatory pathway. Another strategy, being studied in Italy, uses sulfated T3, which is inactive until absorbed and then steadily converted to active T3 by a desulfatase enzyme in the liver. Availability of either slow-release option within the next decade would significantly advance patient care.
Book and Nuanced View
Copied to clipboard!
(02:17:02)
  • Key Takeaway: Effective hypothyroidism management exists between the extremes of TSH-only normalization and unproven elixir treatments.
  • Summary: Dr. Bianco’s book, Rethinking Hypothyroidism, aims to guide patients and physicians toward a nuanced middle ground in thyroid care. This middle ground acknowledges that simply normalizing TSH with T4 is often insufficient for symptomatic patients. The author receives daily feedback from patients whose lives improved after convincing their doctors to start combination therapy.